MXPA99010187A - Method of improving disturbed behavior and elevating mood in humans - Google Patents
Method of improving disturbed behavior and elevating mood in humansInfo
- Publication number
- MXPA99010187A MXPA99010187A MXPA/A/1999/010187A MX9910187A MXPA99010187A MX PA99010187 A MXPA99010187 A MX PA99010187A MX 9910187 A MX9910187 A MX 9910187A MX PA99010187 A MXPA99010187 A MX PA99010187A
- Authority
- MX
- Mexico
- Prior art keywords
- dronabinol
- patients
- dementia
- behavior
- administered
- Prior art date
Links
- 230000036651 mood Effects 0.000 title abstract description 16
- 230000003028 elevating Effects 0.000 title 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims abstract description 66
- 229960004242 dronabinol Drugs 0.000 claims abstract description 64
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 claims abstract description 63
- 229940033529 Tetrahydrocannabinol Drugs 0.000 claims abstract description 63
- 206010012289 Dementia Diseases 0.000 claims abstract description 37
- 230000001430 anti-depressive Effects 0.000 claims description 7
- 239000000935 antidepressant agent Substances 0.000 claims description 7
- 229940005513 ANTIDEPRESSANTS Drugs 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 6
- 239000004089 psychotropic agent Substances 0.000 claims description 6
- 241000282414 Homo sapiens Species 0.000 claims description 5
- 150000001557 benzodiazepines Chemical class 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 3
- 230000000701 neuroleptic Effects 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 abstract description 5
- 230000006399 behavior Effects 0.000 description 28
- 239000000203 mixture Substances 0.000 description 19
- 239000000902 placebo Substances 0.000 description 19
- 229940068196 placebo Drugs 0.000 description 19
- 230000000694 effects Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 11
- 241000282412 Homo Species 0.000 description 9
- 206010001897 Alzheimer's disease Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 6
- 229960003991 Trazodone Drugs 0.000 description 5
- PHLBKPHSAVXXEF-UHFFFAOYSA-N Trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 5
- 230000000750 progressive Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010002855 Anxiety Diseases 0.000 description 4
- 206010057666 Anxiety disease Diseases 0.000 description 4
- 210000003169 Central Nervous System Anatomy 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000003252 repetitive Effects 0.000 description 4
- 230000001702 transmitter Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N Alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 240000000218 Cannabis sativa Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- LNEPOXFFQSENCJ-UHFFFAOYSA-N Haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 3
- 206010027940 Mood altered Diseases 0.000 description 3
- 229960002073 Sertraline Drugs 0.000 description 3
- VGKDLMBJGBXTGI-SJCJKPOMSA-N Sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 3
- 229960004538 alprazolam Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000002354 daily Effects 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- KLBQZWRITKRQQV-UHFFFAOYSA-N dl-Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 3
- -1 for example Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229960003878 haloperidol Drugs 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229960004391 lorazepam Drugs 0.000 description 3
- 230000002035 prolonged Effects 0.000 description 3
- 229940001470 psychoactive drugs Drugs 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 229960002784 thioridazine Drugs 0.000 description 3
- 230000000699 topical Effects 0.000 description 3
- 230000001755 vocal Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CYQFCXCEBYINGO-ZYMOGRSISA-N (6aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-ZYMOGRSISA-N 0.000 description 2
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 2
- 206010002942 Apathy Diseases 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 208000008581 Brain Disease Diseases 0.000 description 2
- 102000018208 Cannabinoid receptor family Human genes 0.000 description 2
- 108050007331 Cannabinoid receptor family Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- 241001539473 Euphoria Species 0.000 description 2
- 206010015535 Euphoric mood Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 206010027951 Mood swings Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229960000762 Perphenazine Drugs 0.000 description 2
- 206010039740 Screaming Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Tranquisan Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 2
- 210000002700 Urine Anatomy 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 239000003557 cannabinoid Substances 0.000 description 2
- 230000002149 cannabinoid Effects 0.000 description 2
- 229930003827 cannabinoid Natural products 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 229960003914 desipramine Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000004634 feeding behavior Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000012765 hemp Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000012766 marijuana Nutrition 0.000 description 2
- 210000002569 neurons Anatomy 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002393 scratching Effects 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960004660 thiothixene Drugs 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 210000004958 Brain cells Anatomy 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229940109239 Creatinine Drugs 0.000 description 1
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N Dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 201000010374 Down syndrome Diseases 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N Doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960005426 Doxepin Drugs 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010016256 Fatigue Diseases 0.000 description 1
- 210000003608 Feces Anatomy 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 206010019233 Headache Diseases 0.000 description 1
- 201000001971 Huntington's disease Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 206010068202 Leukodystrophy Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229940099262 Marinol Drugs 0.000 description 1
- 206010027175 Memory impairment Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 229940100691 Oral Capsule Drugs 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 201000011585 Pick's disease Diseases 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 210000000582 Semen Anatomy 0.000 description 1
- 206010041466 Speech disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000004243 Sweat Anatomy 0.000 description 1
- 230000037034 TERMINAL HALF LIFE Effects 0.000 description 1
- 210000001138 Tears Anatomy 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003474 anti-emetic Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000003542 behavioural Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001149 cognitive Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000003412 degenerative Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000021271 drinking Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002996 emotional Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 201000011240 frontotemporal dementia Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 230000003933 intellectual function Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000002199 language disease Diseases 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 201000009843 lipid storage disease Diseases 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000001975 sympathomimetic Effects 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Abstract
A method for improving disturbed behavior and negative mood in animals suffering from dementia, particularly humans suffering from Alzheimer's type dementia, by administration of dronabinol.
Description
METHOD TO IMPROVE DISRUPTIVE BEHAVIOR AND TO RAISE HUMAN ENCOURAGEMENT RELATED APPLICATIONS This application claims priority over the US provisional patent application No. of. Series 60 / 045,813, which was filed on May 7, 1997 and on the American utility patent application Serial No. 08/866, 511, which was filed on May 30, 1997. GOVERNMENT SUPPORT This invention was conducted with the support of the Government through the Department of Veterans Affairs. The Government may have certain rights over this invention. TECHNICAL FIELD OF THE INVENTION The present invention relates, in general terms, to methods for improving deranged behavior and bad mood in animals, and more specifically said invention relates to methods for improving deranged behavior and bad mood in humans. who suffer from dementia, especially of the Alzheimer type. BACKGROUND OF THE INVENTION Dementia usually refers to a clinical syndrome composed of memory deficiency and loss of other intellectual functions due to chronic progressive degenerative brain disease. Dementia is usually characterized by the gradual loss of intellectual abilities. However, certain abnormalities of behavior and changes in personality are also associated with dementia. There are several states of dementia of multiple causes and different mechanisms. The chronic degeneration of neurons is one of many causes. The majority of dementia diseases appear during semen and many others appear during late adult life. Since the elderly population increases both in percentage of population and in absolute numbers in the Western world, the magnitude of the medical problems presented is alarming. However, dementias are not a consequence of aging. They are diseases linked to age. One of the most common dementias is Alzheimer's dementia (DAT). Alzheimer's disease is a degenerative disease that occurs frequently and that has a devastating nature. Although the disease is very rare in young people, (except in the case of young people with Down syndrome) and it is a rare disease in adults, it is the most frequent cause of dementia in the elderly and is related to depression for patients and their families as well as economic losses resulting from the costs related to the long-term care of patients disabled by the disease. Its prevalence in people older than 80 years is higher than 20%. Alzheimer's disease is frequently associated with a loss of initiative, irritability, loss of interest, forgetfulness, mood swings that often take the form of apathy, as well as excessive mood swings (ie, easy fluctuation between laughter and tears). at the least provocation). Dementia of the Alzheimer type also causes a progressive loss of learned behaviors such as the ability to feed, speech and language disorders, and lack of coordination of voluntary movement. There is therefore a need to have a method to improve the deranged behavior and to improve the mood of patients suffering from dementia. Dronabinol is a cannabinoid that has the chemical designation: (6aR-trans) -ßa, 7, 8, 10a-tetrahydro-6, 6, 9-trimethyl-3-pentyl-6H-dibenzo (b, d) pyran-1 -ol and is also known as delta-9-tetrahydrocannabinol (delta-9-THC). It occurs in nature and has been extracted from Cannabis sativa L. (marijuana). It can also be chemically synthesized. Dronabinol is currently marketed in a formulation having the trademark Marinol® for the treatment of anorexia associated with weight loss in patients with AIDS, and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have not responded adequately to conventional antiemetic treatments. See Physicians Desk Reference 1997. Studies in patients with AIDS have shown good mood or a feeling of well-being after treatment with dronabinol. Gorter, R., Oncology, 5 (Supplement): 13-17 (1991); Beal et al., J. Pain Sympt. Manag., 10: 89-97 (1995). However, prior to the present invention, dronabinol had not been used or suggested for use in patients with dementia, Alzheimer's patients, particularly, to improve the deranged behavior or to elevate the mood of these patients. Accordingly, it is an object of the present invention to provide a method for improving deranged behavior and for improving mood in patients suffering from dementia, especially of the Alzheimer type. SUMMARY OF THE INVENTION In accordance with the present invention, it has now been discovered that certain manifestations associated with dementias can be effectively treated with dronabinol. Specifically, the present invention focuses on a method for improving the deranged behavior of humans suffering from dementia, said method comprising administering an effective amount of dronabinol. The present invention also provides a method for improving negative mood in humans suffering from dementia, said method comprising administering an effective amount of dronabinol. The methods of the present invention are especially beneficial when applied to patients suffering from Alzheimer's dementia. In the methods of the present invention, dronabinol can be administered alone or in combination with a pharmaceutically effective carrier or other pharmaceutically acceptable additives. In addition, the methods of the present invention can be administered in any suitable manner, including oral, buccal, sublingual, subcutaneous, intramuscular, intravenous, transdermal, and rectal administration, as well as other methods. The amount of dronabinol administered can vary widely. For example, the amount may be from about 0.01 to 35 mg / kg of body weight administered one to five times a day. In addition, dronabinol can be administered concurrently or successively with other drugs, such as, for example, psychoactive drugs. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a graph identifying changes in the outcome of the Cohen-Mansfield Agitation Inventory during the period of placebo treatment and the period of dronabinol treatment. Figure 2 is a graphical representation identifying changes in the Negative Affectation result during the period of placebo treatment and the period of dronabinol treatment. DETAILED DESCRIPTION OF THE INVENTION In general, the present invention focuses on a method for improving deranged behavior in humans suffering from dementia by administering an effective amount of dronabinol. The present invention also focuses on a method for improving negative mood in humans suffering from dementia through the administration of an effective amount of dronabinol. The method of the present invention can be used to treat any type of deranged behavior or negative mood, but more preferably it is used to treat the deranged behavior and negative mood associated with dementia in humans. There are several diseases and medical conditions associated with human dementia for which dronabinol may be useful, including Alzheimer's disease, Pick's disease, Huntington's chorea, leukodystrophies, lipid storage diseases such as lipofusinosis, Creutzfeltd-Jakob, dementia due to multiple infarction, post-traumatic dementia, intracranial masses, normal pressure hydrocephalus. Particularly, the method of the present invention improves deranged behavior and elevates mood in patients suffering from Alzheimer's dementia. Although dementias are associated with various clinical manifestations, in a preferred embodiment of the methods of the present invention, dronabinol can improve the various deranged behaviors found in patients affected by dementia., including, but not limited to, aimless displacement, inappropriate dressing, spitting, uttering high-sounding words or verbal aggression, constant unjustified request for attention or help, repetitive prayers or questions, beating, kicking, grabbing people, pushing, throwing things, making strange noises, screaming, biting, scratching, trying to get to a different place, fall intentionally, complain, be negative, eat / drink inappropriate substances, injure or injure others, handle things inappropriately , hide things, store things, break things, or destroy property, perform repetitive movements, make sexual proposals, general restlessness, and strange movements or make faces. In addition, the method of the present invention can raise the mood of patients suffering from any of the following mood states, including, but not limited to, anger, anxiety or fear, and depression or sadness. Although many types of dementia frequently affect humans 65 years and older, the method of the present invention can be applied to any insane patient regardless of age. Dronabinol can also be administered to a demented patient regardless of the duration of the period of time during which the patient has been affected by said dementia, either one day or many years. In addition, dronabinol can be administered to a demented patient for the entire time required up to improvement of the deranged behavior or elevation of the patient's mood. Dronabinol is a cannabinoid that has complex effects on the central nervous system (CNS), including central sympathomimetic activity. Cannabinoid receptors have been discovered in neural tissues. It is believed that these receptors can play a role in measuring the effects of dronabinol on the central nervous system. Alzheimer's disease and other progressive dementias cause the death of nerve cells. This causes the brain to have no substances, such as neurotransmitters, which are necessary for normal brain function. These substances stimulate specific receptors and coordinate the function of brain cells. Even though the endogenous transmitter that stimulates cannabinoid receptors is unknown, it is believed to exist. Therefore, it is postulated that certain symptoms observed in Alzheimer's disease are due to the lack of this endogenous transmitter. The administration of dronabinol can replace the lack of this endogenous transmitter. It is theoretically stated that the administration of dronabinol can replace the lack of this endogenous transmitter and improve brain function affected by cell loss. It is further considered that dronabinol may have a prolonged effect on deranged behavior and bad mood. For example, it has been reported that tetrahydrocannabinol metabolites are present in the urine up to 77 days after the ingestion of marijuana (Ellis et al., Clin. Pharmacol. Ther., 38: 572-78 (1985)). The pharmacokinetic characteristics of dronabinol can be described through a four compartment model, with an initial half-life of four hours and a terminal half-life of 25-36 hours (Aguerrí et al., Pharmacol. Rev., 38: 21-43 (1986)). However, low levels of dronabinol metabolites have been detected in urine and faeces 2-5 weeks after the onset of supervised abstinence (Dackis et al., Am. J. Psychiatry, 139: 1196-98 (1982) ). Even though dronabinol affects the central nervous system, it is not believed to increase paranoid reactions and hallucinations, confusion, ataxia, or speech difficulties that would affect the cognitive or functional abilities of Alzheimer's patients. In accordance with the methods of the present invention, dronabinol can be administered in the form of a composition, including a pharmaceutical composition, comprising dronabinol. Preferably, the composition additionally comprises a pharmaceutically acceptable carrier. One skilled in the art will observe that suitable methods of administration of dronabinol compositions of the present invention to an animal, such as a mammal, are available and, although more than one route of administration of a particular composition may be employed, a A particular route can cause a more immediate and more effective reaction than another route. Pharmaceutically acceptable carriers are also well known to those skilled in the art. The choice of the vehicle will be determined, in part, both by the particular composition and by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of the pharmaceutical compositions of the present invention. Suitable specific forms of administration include oral forms, buccal and sublingual forms of administration, subcutaneous, transdermal, intramuscular or intravenous forms of administration and rectal forms of administration, as well as forms by inhalation. For topical application, the compounds according to the present invention can be used in creams, ointments or lotions. The pharmaceutical compositions of the present invention for oral, buccal, nasal, sublingual, subcutaneous, intramuscular, intravenous, topical, transdermal or rectal administration, dronabinol can be administered in prolonged or controlled release forms or in unitary administration forms mixed with carriers. Pharmaceutical standards to humans or animals. The formulations can conveniently be prepared by any of the methods well known in the art. Formulations suitable for oral administration may consist of (a) liquid solutions, such as for example an effective amount of dronabinol dissolved in diluents such as water, oil or saline, (b) capsules, sachets, or tablets, each containing a predetermined amount of the active ingredient, such as solids or granules, (c) suspensions in an appropriate liquid, and (d) suitable emulsions. The tablet forms may include one or more of the following: lactose, mannitol, corn starch, potato starch, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents, wetting agents, preservatives, flavors, and pharmacologically compatible vehicles. The tablets may comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as tablets comprising the active ingredient in an inert base, such as for example gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing , in addition to the active ingredient, these vehicles as is known in the art. Dronabinol, alone or in combination with other suitable components, can be prepared in aerosol formulations for administration by inhalation. These aerosol formulations can be placed in acceptable propellants under pressure, such as, for example, dichlorodifluoromethane, propane, nitrogen, and the like. Formulations suitable for parenteral administration include aqueous and non-aqueous solutions, sterile isotonic injection solutions, which may contain anti-oxidants, regulators such as for example acetate and phosphate, toxicity adjusting agents, such as for example sodium chloride, pH, such as for example hydrochloric and phosphoric acid, bacteriostats, and solutes that make the formulation isotonic with the blood of the intended recipient, as well as sterile aqueous and non-aqueous suspensions which may include suspending agents, solubilizers, thickening agents, stabilizers and preservatives. The formulations may be presented in single dose or multiple dose sealed containers, such as ampoules and flasks, and may be stored in a lyophilized condition that requires only the addition of the sterile liquid vehicle, eg, water for injections, immediately prior to use. . Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the type previously described. In a preferred embodiment, the dronabinol is administered in the form of an oral capsule composition containing 2.5 mg, 5 mg, or 10 mg of dronabinol, sesame oil, gelatin, glycerin, methyl paraben, propyl paraben, and titanium dioxide. The dose administered to an animal, particularly a human being, in the context of the present invention should be sufficient to obtain a therapeutic response within a reasonable time frame. The dose is determined by the strength of the particular compositions employed and the condition of the person, as well as the body weight of the person to be treated. The size of the dose will also be determined by the existence, nature, and magnitude of the adverse side effects that may accompany the administration of a particular composition. A suitable dosage for internal administration is 0.01 to 100 mg / kg per day. The preferred dosage is 0.01 to 35 mg / kg per day. A more preferred dosage is 0.05 to 5 mg / kg per day. A suitable concentration of dronabinol in pharmaceutical compositions for oral administration is 0.05 to 15% (by weight). A preferred concentration is 0.02 to 5%. A more preferred concentration is from 0.1 to 4%. They are especially orally administered from 0.03 to 0.06 mg / kg of body weight per day, and more preferably, a dosage form of oral 2: 5 mg is administered twice a day. The most preferred dosage for extracorporeal administration is within a range of about 0.1 mg / kg to 5 mg / kg of body weight per day.
In the case of rectal administration route, topical
(including buccal and sublingual) or transdermal, the preferred dosage (estimated as the base) is within a range of 0.05 mg / kg to 20 mg / kg of body weight per day. Even when dronabinol can be administered as needed, preferably dronabinol is administered one to five times a day. Dronabinol can be administered concurrently with other necessary medications. For example, one or several psychoactive medications can be administered before, concurrently and after treatment with dronabinol. Examples of psychoactive drugs of this type include, but are not limited to, antidepressants, neuroleptics and benzodiazepines. Specific neuroleptic drugs include, but are not limited to, ferfenazine, thiothixene, haloperidol, and thioridazine. Specific benzodiazepines include, but are not limited to, lorazepam and alprazolam. Specific antidepressants include, but are not limited to, sertraline, trazodone and desipramine. Although the preferred embodiment of the present invention is the treatment of dementia, particularly of the Alzheimer's type, in humans, the methods of the present invention can be used to treat deranged behavior and to elevate mood in animals of any type. Examples of suitable animals include, but are not limited to, dogs, pigs, sheep, horses, cows and cats. All publications mentioned or referenced here are incorporated by reference in their entirety. The present invention will be further illustrated through the following example. This example serves to further illustrate the present invention and is not intended to limit the scope of said invention. EXAMPLE Each patient in this example was diagnosed with "probable" DAT by a neurologist in accordance with DSM III-R and criteria NINCDS-ARDDA. These generally accepted criteria include deficits in two or more areas of cognition, progressive worsening of memory and other cognitive functions, no disturbances of consciousness, absence of systemic disorders, and other brain diseases that, in themselves, could explain the progressive deficits of memory and cognition. (McKhann et al., Neurology, 34: 939-944 (1984).) Each patient underwent a physical examination and a laboratory examination including complete blood count with differential liver function tests, thyroid function tests including TSH , BUN iron binding capacity, creatinine, and electrolytes The severity of dementia in each patient was measured by the Mini-mental Status Examination (MMSE) .The MMSE is generally known in the art and is is described in Folstein et al., J. Psychiatr Res., 12: 189-198 (1975), Katz Activity of Daily Living scale (Katz ADL) (Katz et al., JAMA, 185: 914-19 (1963) , and Bedford Alzheimer's ursing Scale-Sverity (BANS-S) (Bedford's Alzheimer's Care severity scale) (Volicer et al., J. Gerontol., 49: M223-26 (1994).) These data are reported in Table 1
Table 1 Average characteristic + deviation standard range * Age (years) 72.7 + 4.9 65 - 82 Sex 11 male sex 1 female DAT duration (years) 7.0 + 4.1 2 - 16
Duration of care of 17.4 _ + 21.9 2.6 - 81.0 long term before the start of the study (months) Result of mini-examination of 4.0 + 7.4 0 - 20 mental state (11) Result of the activity 5.7 + 0.6 4 - 6 of Katz of the daily life (12) severity score according to 17.5 + 3.0 13 - 22 Bedford's Alzheimer's care scale (13) * SD it refers to the standard deviation. The patients included in the analysis were all 65 years of age or older and all patients except one were men. The duration of DAT ranged from 2 to 16 years and most patients had undergone institutional long-term care for many months before the start of the study. Most of them looked like severe dementia; the result of MMSE was 0 in 8 patients. The patients also had affected activities of daily life; 9 were dependent on the 6 activities. The results of BANS-S, which detect the progression of the disease even in the severe stage, indicated a moderate to severe affectation. Eleven of the patients were taking a psychoactive drug before the start of the study with dronabinol and they continued with the ingestion of this drug during the study period. Four patients were receiving regular doses
of neuroleptics (perphenazine, thiothixene, haloperidol or dflfc thioridazine), 4 patients were receiving regular doses of benzodiazepines (3 received lorazepam and 1 alprazolam), and 8 patients were receiving regular doses of antidepressants. Antidepressants included sertraline (8
patients), trazodone (4 patients) and desipramine (1 patient), 9 three patients were receiving both sertraline and trazodone, and one patient was switched from trazodone to doxephema.Treatment with antidepressants was initiated at least 4
weeks before the start of the study and the average duration of antidepressant treatment before the start of the study was 7 months. Eleven patients presented orders for psychoactive drugs as needed (PRN). These drugs included lorazepam in 4 patients and alprazolam,
trazodone, doxepin, haloperidol, perphenazine and thioridazine in one patient each. Patients received these drugs very rarely, on average 9.7 doses / 6 weeks during the administration of placebo and 7.2 doses / 6 weeks during treatment with dronabinol. A double-blind placebo-controlled cross-over design was employed with each study period lasting 6 weeks. Dronabinol or placebo was administered in a fixed dose schedule, 2.5 mg capsule or placebo capsule with identical appearance every morning at 12 o'clock. Patients were randomly assigned to placebo groups first or dronabinol first. Possible side effects were determined each week by asking primary care staff if the patient had a list of possible symptoms. A list of these symptoms was observed in 12 patients over seventy weeks in accordance with what is identified in Table 2 below. Table 2 SYNTOMA DRONABI OL PLACEBO Patients Weeks Patients Weeks n * nnn Anxiety / 11 92 37 53 12 100 43 61 nervousness Affectation 11 92 32 46 10 83 36 51 emotional Tiredness 9 75 25 36 42 15 21 Sleepiness 8 67 29 41 4 33 12 17
Euphoria 7 58 31 44 5 42 16 23
Reaction 4 33 16 23 5 42 18 26 paranoid Hallucination 4 33 11 16 5 42 16 23
Depression 2 16 4 6 2 16 4 6
Ataxia 2 16 6 8 2 16 3 4
Pain 2 16 7 10 1 8 3 4 muscular Diarrhea 2 16 3 4 Blushing 1 8 2 3 2 16 2 3
Confusion 1 8 2 3 2 16 2 3 increasing sweat 1 8 2 3 1 8 1 1
Difficulty 1 8 1 1 increasing speech Headache 1 8 1 1 Nightmares 1 8 1 1
* refers to the number of patients who had the listed effect and% identifies the percentage of total patients who had the effect. In addition to the listed effects, an attack incidence was observed in a patient treated with dronabinol. The baseline measurements were taken one week prior to randomization and initiation of treatment. Behavioral measurements were obtained weekly during the 12-week duration of the trial. Repeated measurements of these variables were therefore available for six weeks of treatment with dronabinol and six weeks of placebo treatment for each patient. The magnitude of disordered behavior presented by each patient was determined each week through interviews with primary health care personnel, who were family members, based on the patient's behavior rating scales. Deranged behavior was measured by the Cohen-Mansfield Agitation Inventory (CMAI) (Cohen-Mansfield Agitation Inventory (Cohen-Mansfield et al., J. Gerontol, Med. Sci., 44: M77-84 (1989)) which It is a widely used instrument with good psychometric properties, Twenty-nine elements of this inventory are scored through frequency (1 = never and 7 = constantly or almost constantly) and by the level of disorder (from 1 = no disorder to 5 = disorder For each observation period, the total result was calculated by multiplying the frequency and impact of the disorder of the individual elements and by adding the products.The elements of CMAI observed are identified in Table 3 below: TABLE 3 - ELEMENTS OF BEHAVIOR OF CMAI OBSERVED Speed, displacement without direction Inappropriate dress, undress Spit (including during food) Use of high-sounding words or verbal aggression Constant unjustified request for attention or help Repetitive prayers or questions (beating (including self-kicking) Kicking Holding on to people Pushing Throwing things Strange noises (strange laughter or whining) Screaming Biting Scratching Attempting to get to a different place (for example, outside the ward) Intentional falling Complaints Negative condition Eating / drinking inappropriate substances Hurting yourself or others (hot water, for example) Handling things inappropriately Hide things Store things Break things or destroy properties Perform repetitive acts 5 Make unseemly verbal proposals General uneasiness Strange movements, making faces Acceptance of patients was measured using Lawton
Observed Affect Scale - Past (Lawton et al., J. Gerontol.
(B), 51B: P3-14 (1996)). This scale consists of six elements, three that measure the positive affectation (pleasure, interest and happiness) and three that measure the negative affectation
(anger, anxiety / fear and depression / sadness) on a scale of
points (from 1 = never to 5 = more than 3 times a day). The 15 results of the positive and negative affectations were calculated by adding the results of the appropriate elements. Statistical analysis was carried out using Statistix
4. 1 (Analytic Software). Repeated ANOVA measurements during the 12 weeks of the study were carried out to test the effects of the variables of order, time and treatment under study. Figure 1 is a graphical representation showing the result of CMAI during the placebo and dronabinol phases of the study. Deranged behavior decreased during treatment with dronabinol (F (order x treatment) = 2.18, df = 1143, p = 0.12) and this decrease in deranged behavior persisted during the placebo period after treatment with dronabinol. When the results of CMAI were expressed as a percentage of the baseline, a significant order x time interaction was observed (F = 2.35 (order x time), df = 5.143, P = 0.05). Figure 2 is a graphic representation of the changes in the outcome of negative affectation during the placebo and dronabinol phases. Negative affectation decreased during the study period of 12 weeks (F (time) = 2.46, df = 5, 143, p = 0.045) and decreased more when patients were treated with dronabinol than when patients were treated with placebo (F (time x treatment) = 3.98, df = 5.143, p = 0.004). In addition, the decrease was greater in the case of patients who received dronabinol first, compared with patients who received placebo first (F (order x time) = 5.45, df = 5.143, p <0.0005). In contrast, the positive affectation remained similar during both treatments (dronabinol and placebo) and treatment periods (the six-week dronabinol phase and the six-week placebo phase). We observed a widespread agitation using two scales: CMAI and Observed Affect Scale (Scale of observed affectation). The negative phase of the Observed Affect Scale includes two elements (anger and anxiety / fear) that are commonly present in patients during agitated behaviors. The third element of pressure / sadness was rarely observed as can be seen from Table 2. Therefore, both scales measured similar deranged behaviors. It is possible that this effect is partially due to drowsiness, which is twice as common in patients treated with dronabinol than in patients receiving placebo. The effect of dronabinol on deranged behavior continued during the subsequent placebo period. No differences were observed in deranged behavior in the second treatment period. This prolonged change in disordered behavior could be due to a long-term effect of dronabinol. Treatment with dronabinol did not change the Positive Affectation, even when the euphoria as an adverse reaction was reported more frequently and in a larger number of patients during the treatment with dronabinol than during the periods in which the patients received placebo. It is possible that the elements of Positive Affectation represent more a degree of patient involvement than the patient's mood (Lawton et al., Psicol.Aging, 3: 469-477 (1995)).
While this invention has been described with emphasis on preferred embodiments, it will be apparent to those of ordinary skill in the art that variations as to the preferred methods of the present invention can be employed and that the possibility that the invention is practiced from a differently from what is specifically described here. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the invention, as defined in the following claims.
Claims (1)
- REI INDICATIONS A method for the treatment of humsuffering from dementia, comprising the administration of a therapeutically effective amount of dronabinol to said human beings. The method of claim 1, wherein said dementia comprises Alzheimer's type dementia. The method according to claim 1, wherein said dronabinol is administered in combination with a pharmaceutically effective carrier. The method according to claim 1, further comprising the administration of a psychoactive drug. The method according to claim 4, wherein said psychoactive drug is selected from the group consisting of antidepressants, neuroleptics and benzodiazepines. The method according to claim 1, wherein dronabinol is administered to said human beings orally. The method according to claim 6, wherein the dronabinol is administered in an amount of about 0.03 to about 0.06 mg / kg of body weight per day. The method according to claim 6, wherein 2.5 mg of dronabinol are administered twice a day.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/045813 | 1997-05-07 | ||
US045813 | 1997-05-07 | ||
US08866511 | 1997-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA99010187A true MXPA99010187A (en) | 2000-12-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5804592A (en) | Method for improving disturbed behavior and elevating mood in humans | |
Volicer et al. | Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease | |
Lelord et al. | Effects of pyridoxine and magnesium on autistic symptoms—initial observations | |
Holbrook et al. | Diagnosis and management of acute alcohol withdrawal | |
Robinson et al. | Sodium oxybate: a review of its use in the management of narcolepsy | |
EP3215148B1 (en) | Use of low dose of tetrahydrocannabinol for the treatment of cognitive decline in elderly patients | |
Gadow | Children on Medication Volume II: Epilepsy, Emotional Disturbance, and Adolescent Disorders | |
US20150224065A1 (en) | Agent, pharmaceutical composition, and method for treating the ethyl alcohol and/or narcotic dependence | |
AU743788B2 (en) | Method of improving disturbed behavior and elevating mood in humans | |
Diamond | Instant Psychopharmacology 3e | |
MXPA99010187A (en) | Method of improving disturbed behavior and elevating mood in humans | |
Morley et al. | Malnutrition in the elderly | |
Burns | Droperidol in the management of hyperactivity, self-mutilation and aggression in mentally handicapped patients | |
EP0440851A1 (en) | Use of buspirone for the treatment of depressions | |
O'Shaughnessy | BMA New Guide to Medicine and Drugs 8th Edition | |
Hoffer | Allergy, depression and tricyclic antidepressants | |
Adams | The Gordon Wilson Lecture. Nutritional Diseases of the Nervous System in the Alcoholic Patient | |
Roffman | Using marijuana in the reduction of nausea associated with chemotherapy | |
Sood et al. | Pharmacotherapeutic challenges in the management of attention-deficit/hyperactivity disorder and chronic tics in a school aged child | |
George et al. | Cannabis toxicity in children and adolescents | |
Safer | Drug treatment in child psychiatry | |
Wedret | Managing Alzheimer's disease | |
Phelps | How To Keep Your Brain Young: Preserve memory, reduce dementia risk, harness neuroplasticity and restore function | |
Sharpley et al. | Comparison of butaperazine and perphenazine: A double-blind controlled study | |
CN102548550A (en) | Exo-S-mecamylamine method, use, and compound for treatment |